Lilly’s Gemzar For Ovarian Cancer To Be Reviewed by Oncologic Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Oncologic Drugs Advisory Committee will review Gemzar on March 15. The committee’s Pediatric Oncology Subcommittee will discuss Novartis’ Exjade post-marketing study commitments on March 14.